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Abstract: The receptor for advanced glycation end products (RAGE) is oncogenic and 
overexpressed in human cancers, but its role in hepatocellular carcinoma remains unclear. 
Here we demonstrated that RAGE is overexpressed in primary hepatocellular carcinoma 
(PHC) compared to adjacent para-neoplastic liver samples. Serum endogenous secretory 
RAGE levels were also increased in PHC patients (p < 0.01). Moreover, we demonstrated 
that  RAGE  regulates  cellular  proliferation  in  Hepatocellular  carcinoma  (HCC). 
Knockdown of RAGE by specific siRNA inhibited cellular growth in the hepatocellular 
carcinoma cell line, Huh7, whereas the RAGE ligand, high mobility group box 1 protein 
(HMGB1) increased cellular proliferation. In addition, knockdown of RAGE by siRNA 
arrested cells in the G1 phase and inhibited DNA synthesis (p < 0.01), while HMGB1 
protein decreased the number of cells in the G1 phase and increased the number in the 
S phase (p < 0.05). Furthermore, quantitative real time RT-PCR (qRT-PCR) and Western 
Blot  results  demonstrated  that  RAGE  and  HMGB1  positively  regulate  NF-κB  p65 
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expression  in  Huh7  cells.  These  studies  suggest  that  RAGE  and  RAGE  ligands  are 
important targets for therapeutic intervention in hepatocellular carcinoma. 
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1. Introduction 
Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world, especially 
in Asia and Africa [1]. Most cases of HCC are secondary to either a viral hepatitis infection (hepatitis B 
or C) or cirrhosis [2].
 Despite advances in surgical and nonsurgical therapies for hepatocellular cancer, 
there is still no satisfactory method for improving the overall survival rate of affected patients [3]. 
Since  HCC  is  typically  an  inflammation-associated  cancer,  studying  the  molecular  mechanisms 
underlying cancer promotion could be of great benefit to prevent hepatocarcinogenesis. 
The receptors for advanced glycation end products (RAGE) are members of the immunoglobulin 
family which are usually expressed in low levels on a variety of cell types including immune cells, 
neurons,  activated  endothelial  and  vascular  smooth  muscle  cells  and  bone  forming  cells. 
Physiologically, RAGE seems to have a role in embryonic neuronal outgrowth [4]. However, in adult, 
RAGE appears to act primarily in pathological responses including diabetes, inflammation, neuronal 
degeneration and cancers [5–8].  
RAGE ligands fall into several distinct families. They include the High Mobility Group family 
proteins (including the HMGB1); members of the S100 protein family, and some advanced glycation 
end products such as carboxymethyllysine (CMLAGE) [9–12]. 
HMGB1  is  a  member  of  the  non-histone,  chromatin-associated  high  mobility  group  family  of 
proteins [13]. It is widely expressed in many tumor cells and can be secreted by them or be released 
upon  necrotic  cell  death  [14,15].  The  constant  release  of  HMGB1,  which  functions  as  a 
proinflammatory cytokine, from necrotic tumor cells creates a microenvironment similar to chronic 
inflammation;  a  condition  known  to  contribute  to  the  development  of  epithelial  malignancies, 
particularly inflammation-associated cancer [16–18].  
The interactions between RAGE and its ligand trigger the activation of key cell signaling pathways 
(e.g., p38 and p44/42 MAP kinase [19], NF-κB, cdc42/rac [20]), and the generation of reactive oxygen 
species, and result in the production of pro-inflammatory cytokines [18]. NF-κB is a ubiquitous factor 
that controls the expression of genes involved in immune response and inflammation [21]. Its activity 
is regulated by homo- or hetero-dimers formed by members of the Rel/NF-κB family of transcription 
factors. The functional specificity and selectivity of the NF-κB response is thought to arise primarily 
from the binding of Rel/NF-κB complexes to specific DNA regulatory sites (κB sites) of target genes 
in various cell types [22,23].  
To characterize the role of RAGE in the proliferation of HCC, we investigated RAGE expression in 
primary  hepatocellular  carcinoma  (PHC)  neoplastic  and  para-neoplastic  liver  samples.  We  also 
cultured the HCC cell line, Huh7, and diminished expression of RAGE using RAGE specific siRNA. 
Additionally, we activated RAGE using HMGB1. We also used RAGE siRNA and HMGB1 to explore 
the role of RAGE on the expression of the transcriptional factor NF-κB p65. Int. J. Mol. Sci. 2012, 13  5984 
 
 
2. Results and Discussion 
2.1. RAGE Expression in PHC Neoplastic Liver Samples Is Higher than Para-neoplastic Samples 
RAGE  is  overexpressed  in  a  variety  of  human  tumors.  To  determine  whether  RAGE  is 
overexpressed in primary hepatocellular carcinoma, all tissue samples were ground and the cellular 
extracts or protein lysates were prepared and subjected to quantitative real time PCR (qRT-PCR) and 
Western  Blot  analysis.  RAGE  mRNA  and  protein  expression  in  paired  PHC  neoplastic  and  
para-neoplastic  liver  samples  of  the  ten  patients,  demonstrated  that  PHC  neoplastic  liver  samples 
express  significantly  higher  levels  of  RAGE  mRNA  and  protein  than  their  para-neoplastic  paired 
samples  (p  <  0.01),  Figure  1.  qRT-PCR  results  showed  that  RAGE  mRNA  expression  in  each 
neoplastic liver sample was significantly higher than its adjacent para-neoplastic sample (p < 0.01). 
Quantification analysis revealed that the average of RAGE mRNA expression in neoplastic samples 
was 50% higher than para-neoplastic samples.  There was no significant difference in the level of 
RAGE expression between males and females. 
Figure 1. Expression of RAGE mRNA and protein in Primary Cellular Carcinoma (PHC) 
and  their  matched-adjacent  liver  tissues  by  qRT-PCR  and  Western  Blot.  (a)  Relative 
expression  of  RAGE  mRNA  normalized  to  β-actin  expression  (neoplastic  vs.  
para-neoplastic) analyzed by qRT-PCR (average ΔCt of ten samples); (b) Expression of 
RAGE protein by Western Blot; (c) Expression of RAGE protein as a ratio to β-actin. The 
pictures represent the results for 5 patients out of the total 10 patients. In all the patients 
RAGE mRNA and protein expression in PHC tissues was significantly higher than their 
matched-adjacent tissues (* p < 0.01, # p < 0.01). Lanes 2, 4, 6, 8, 10: RAGE expression in 
PHC. Lanes 1, 3, 5, 7, 9: RAGE expression in matched-adjacent liver tissues. M: molecular 
weight marker. Three independent measurements were made and averaged. 
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Figure 1. Cont. 
 
 
 
2.2. RAGE Protein Level in the Sera of PHC Patients Is Higher than That in Controls 
ELISA results demonstrated that RAGE is expressed in the sera of both PHC patients and normal 
control subjects. RAGE protein level in the sera of PHC patients was significantly higher than that in 
normal control subjects (313.34 ±  22.14 ng/L (n = 10), vs. 59.14 ±  4.21 ng/L (n = 10), p < 0.01). There 
was no significant difference in the level of serum RAGE between males and females. 
2.3. RAGE siRNA Decreases Viability in Huh7 Cells, While HMGB1 Increases It 
Huh7 and HepG2 cells were cultured and expression of RAGE mRNA by qRT-PCR was evaluated. 
The results indicated that both Huh7 and HepG2 cells express RAGE mRNA, however, Huh7 cells 
express significantly higher levels of RAGE mRNA (p < 0.01), (Figure 2). According to this result, 
Huh7 was selected to undergo additional investigations.  
Huh7 cells were transfected with R1, R2, R3 or negative control RNA. qRT-PCR and Western Blot 
results demonstrated that R3 had the highest efficiency in inhibiting RAGE gene products (Figure 3). 
Therefore, R3 was selected as the silencing RNA to transfect Huh7 cells. 
Thus, our results suggest that RAGE overexpression in PHC neoplastic liver samples and in the sera 
of  PHC  patients  is  closely  associated  with  hepatocarcinogenesis.  To  explore  whether  RAGE 
contributes to HCC cellular proliferation, Huh7 cells were either transfected with RAGE siRNA or 
treated with HMGB1. MTT results indicated that Huh7 transfected with RAGE siRNA grew more 
slowly than cells transfected with negative control RNA (NC) and blank controls (p < 0.01). The 
greatest growth inhibition was achieved after 48 h of incubation. In contrast, HMGB1 activated the 
growth of Huh7 cells. The greatest increase in cell growth was observed after 24 h of incubation  
(p < 0.01), Figure 4. Int. J. Mol. Sci. 2012, 13  5986 
 
 
Figure  2.  Relative  expression  of  RAGE  mRNA  (normalized  to  β-actin  expression)  by 
HepG2 cells  (vs. Huh7  cells)  analyzed by qRT-PCR; (* p  < 0.01). Three independent 
measurements were made and averaged. 
 
Figure 3. Expression of RAGE mRNA in Huh7 cells after transfection with three different 
RAGE siRNA; R1, R2, R3 and one negative control RNA (NC). (a) Relative expression of 
RAGE mRNA normalized to β-actin expression (vs. blank control) analyzed by qRT-PCR;  
(b) Expression of RAGE protein by Western Blot; (c) Expression of RAGE protein as a 
ratio  to  β-actin.  R3  showed  the  highest  efficiency  in  inhibiting  RAGE  gene  products  
(* p < 0.01, # p < 0.01). Three independent measurements were made and averaged. 
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Figure  4.  Cell  proliferation  was  performed  with  the  3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium  bromide  (MTT)  colorimetric  assay  in  Huh7  cells.  (a)  Cell  growth 
inhibition caused by RAGE siRNA. The greatest growth inhibition was achieved after 48 h 
of incubation (* p < 0.01); (b) Cell growth activation caused by HMGB1. The greatest 
growth activation was observed after 24 h of incubation (# p < 0.01). Three independent 
measurements were made and averaged. NC: Negative Control RNA. 
   
2.4. RAGE siRNA Induces G1 Arrest in Huh7, While HMGB1 Induces DNA Synthesis 
MTT results demonstrated that RAGE is closely related to cellular proliferation. To confirm this 
result, we investigated the effect of RAGE siRNA and HMGB1 on the Huh7 cell cycle. FACS results 
indicated that growth inhibition by RAGE siRNA in the Huh7cells was accompanied by cell cycle G1 
arrest,  which  was  associated  with  a  decrease  in  DNA  synthesis  and  reduction  in  cellular  growth. 
RAGE siRNA appears to inhibit DNA synthesis and increase the percentage of cells in G1 phase. After 
24 h of treatment, the percentage of G1 phase cells was 75.59 ±  2.63% in the RAGE siRNA-treated 
group compared with 54.96 ±  3.47% in the negative control (NC) and 55.34 ±  3.22% in the blank 
control (p < 0.01). This increase was coupled with a decreased percentage of cells in S-phase. After 24 h 
of treatment, the percentage of S-phase cells was 14.10 ±  2.74% in the RAGE siRNA-treated group 
compared with 34.25 ±  3.37% in the negative control (NC) and 35.59 ±  3.93% in the blank control  
(p < 0.01). In contrast, HMGB1 induced DNA synthesis and decreased the percentage of cells in G1 
phase.  After  24  h,  the  percentage  of  G1  cells  was  47.64  ±   3.21%  in  the  HMGB1-treated  group 
compared with 55.27 ±  2.86% in the blank control (p < 0.05). This decrease was coupled with an 
increased percentage of cells in S-phase. After 24 h of treatment, the percentage of cells in S-phase 
was 39.13 ±  3.57% in the HMGB1-treated group compared with 34.38 ±  2.43% in the blank control  
(p < 0.05), Figure 5. Int. J. Mol. Sci. 2012, 13  5988 
 
 
Figure 5. Cell cycle contribution of Huh7 detected by flow cytometry staining treated with 
RAGE siRNA or HMGB1. RAGE siRNA inhibited DNA synthesis, significantly increased 
the percentage of cells in G1 phase and significantly decreased the percentage of cells in  
S-phase 24 h post-treatment (* p < 0.01). However, HMGB1 induced DNA synthesis, 
significantly decreased the percentage of cells in G1 phase and significantly increased the 
percentage  of  cells  in  S-phase  24  h  post-treatment  (#  p  <  0.05).  Three  independent 
measurements were made and averaged. 
   
 
   
2.5. RAGE siRNA Decreases the Expression of NF-κB p65 in Huh7 Cells, While HMGB1 Increases It 
NF-B alters cell behavior in many ways. It inhibits apoptosis, increases cell proliferation, and 
increases  inflammatory  and immune response.  Recent  evidence suggests  that activation of  NF-κB 
contributes to the development of several types of human cancer. Accordingly, we investigated the role 
of RAGE siRNA and HMGB1 on Huh7 expression of NF-κB p65. Huh7 cells were either transfected 
with RAGE siRNA or treated with HMGB1. qRT-PCR and Western Blot results demonstrated that 
RAGE siRNA significantly decreased the  expression of NF-κB  p65 (Figure  6a,c),  while HMGB1 Int. J. Mol. Sci. 2012, 13  5989 
 
 
significantly increased it (Figure 7a,c). qRT-PCR revealed that RAGE siRNA decreased the expression 
of NF-κB p65 by 68% (p < 0.01, vs. blank group, Figure 6a) while HMGB1 increased the expression of 
NF-κB p65 mRNA by 42% (p < 0.01, vs. blank group, Figure 7a). 
Figure 6. The effect of RAGE siRNA on the expression of NF-κB p65 in Huh7 cells by 
qRT-PCR and Western Blot. (a) Relative expression of NF-κB p65 mRNA normalized to 
β-actin expression (vs. blank control) analyzed by qRT-PCR; (b) Western Blot protein 
bands film results; (c) Expression of NF-κB p65 protein as a ratio to β-actin; (* p < 0.01,  
# p < 0.05). Three independent measurements were made and averaged. NC: Negative 
Control RNA. 
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Figure 7. The effect of HMGB1 on the expression of NF-κB p65 in Huh7 cells by qRT-PCR 
and Western Blot. (a) Relative expression of NF-κB p65 mRNA normalized to β-actin 
expression (vs. blank control) analyzed by qRT-PCR; (b) Western Blot protein bands film 
results;  (c)  Expression  of  NF-κB  p65  protein  as  a  ratio  to  β-actin;  (*  p  <  0.01, 
 # p < 0.05). Three independent measurements were made and averaged.  
 
 
 
2.6. Discussion 
HCC is one of the most common forms of malignancy in humans worldwide, representing 40% of 
all the cancers in Southeast Asia, Japan, and Africa and 2%–3% of all the cancers in United States [24].  
RAGE is expressed in a variety of human tumors, including ovarian, breast, colonic, brain, lung, 
prostate, lymphoma, and melanoma [25]. In most pathologic conditions in which it plays an important 
role, RAGE levels are found to be elevated [26–29]. Our results demonstrated a significant increase in 
RAGE expression in PHC liver samples comparing to their adjacent normal tissues. In addition, it 
showed for the first time a significant increase in RAGE serum levels in PHC patients compared to 
normal control subjects. Although the sample size in this part of the study was relatively small, the 
results  gave  us  good  introductory  guidelines  for  our  investigations  on  HCC  cell  lines  which 
demonstrated that RAGE siRNA decreases Huh7 cellular proliferation, increases the number of Huh7 
cells in the G1 phase and decreases their number in the S phase. This strongly correlates RAGE 
function to HCC growth and proliferation, and shows that inflammatory signals initiated by RAGE 
contribute greatly with hepatocarcinogenesis. Int. J. Mol. Sci. 2012, 13  5991 
 
 
During our investigations on Huh7 cells, we chose the concentration of HMGB1 according to the 
results  of  MTT  assay.  The  results  demonstrated  that  100  ng/mL  of  HMGB1  could  significantly 
increase Huh7 cellular proliferation. Although Huh7 cells are expected to secrete HMGB1, it appears 
that adding exogenous HMGB1 amplifies the proinflammatory effect of the secreted HMGB1.  
Promotion of cancer by HMGB1-RAGE interaction was demonstrated in various cancers, such as 
gastric cancer [30], colon cancer [31], breast cancer [26], melanoma [32], and prostate cancer [28]. On 
the other hand, previous studies showed that HMGB1 activates signaling pathway involving protein 
kinase B (AKT), mitogen-activated protein kinases (MAPKs), and NF-κB which play important roles 
in tumor growth [33]. Our results demonstrated that HMGB1 increases the expression of NF-κB p65, 
increases the number of cells in the S phase, and as a result increases the proliferation of Huh7 cells. 
This  correlates HMGB1 to cellular proliferation,  and  completes the chain  which starts with HMGB1 
binding to RAGE, the activation of NF-κB and ultimately faster rate of cell proliferation and tumor growth. 
In this study, we decreased the expression of RAGE through RAGE specific siRNA and found that 
NF-κB p65 expression was decreased. On the other hand, we activated RAGE using HMGB1 and 
found that expression of NF-κB p65 was increased. This correlates RAGE activity to NF-κB p65 
expression and confirms that RAGE activation perpetuate NF-κB p65 activation by de novo synthesis 
of  NF-κB  p65.  Thus  this  pathway  produces  a  constantly  increasing  pool  of  NF-κB  p65  which  is 
directly associated with cell proliferation.  
Experimental evidence demonstrated that NF-κB binding to cyclin D1 promoter is critical for the 
regulation of cyclin D1 expression [34]. This indicates that signal transduction begins with RAGE 
through NF-κB leading to enhanced expression of cyclin D1 which in turn leads to a rapid progression 
from G1 to S phase and an increased rate of division and proliferation of cancer cells. Moreover, the 
increase  in  RAGE  expression  is  thought  to  be  due  to  a  positive  feedback  loop  from  the  RAGE 
promoter through RAGE activation of NF-κB [35].  
Taking together, we demonstrated that interfering with RAGE activity through the use of specific 
siRNA  could  be  of  great  benefit  in  reducing  the  proliferation  of  hepatocellular  carcinoma.  This 
indicates that RAGE gene is a potential target for future gene therapy researches to find treatments for 
many malignancies, including HCC. In addition, several studies have addressed the identification of 
putative NF-κB inhibitors as therapeutic agents for cancer. Since NF-κB activation is the result of a 
multi-step signaling pathway, these agents may target different points of the signaling process. Other 
means to reduce cellular proliferation could be through the use of RAGE blocking antibodies which 
needs further investigations.  
3. Experimental Section 
3.1. Patients and Controls 
This part of the study included 10 cases of primary hepatocellular carcinoma (PHC). Liver tumors 
in those patients were removed surgically in the department of General Surgery, Xiangya Hospital of 
Central South University, during the period June 2010–August 2010. The neoplastic, correspondent 
para-neoplastic  tissues  and  blood  samples  of  the  patients  were  collected.  All  liver  samples  were 
independently reviewed and diagnosed by two pathologists. Exclusion criteria included patients with Int. J. Mol. Sci. 2012, 13  5992 
 
 
severe  infection,  sepsis,  end-stage  renal  failure,  diabetes,  neurological  disease,  patients  using 
immunomodulatory drugs and patients who underwent radiotherapy during past three months. Of the 
ten cases, seven were males and three were females, average age 46.7 ±  15.3 years. Other characteristics 
of the patients were presented in Table 1. During the same period of time, 10 blood samples were 
collected from healthy volunteers (7 males and 3 females); average age 41.6 ±  12.7 years, as a control. 
Written informed consent to use the samples for research was obtained from the patients and clinicians. 
The present study protocol was approved by the ethical committee at Xiangya Hospital of Central 
South University, Changsha, China. 
Table 1. Clinical characteristics of PHC patients enrolled in the study 
Number of patients  10 
Male/Female  7/3 
Mean age (average)  46.7±15.3 years 
HBsAg（+）  8 
HBV-DNA  8（102 ~106 copies/ml） 
Anti-HCV (+)  2 
HCV-RNA（+）  1（105 copies/ml） 
Cirrhosis  7 
ELISA 
Blood samples were kept for 10–20 min to coagulate and then centrifuged at 3000 rpm for 20 min. 
Supernatants were collected and RAGE expression was analyzed by ELISA (Abcam, USA) according 
to the manufacturer instructions. Three independent measurements were made and averaged. 
3.2. Cell Culture 
Human hepatocellular carcinoma cell lines Huh7 and HepG2 were stored in our laboratory. Huh7 
cells were cultured in RPMI 1640 medium (Invitrogen, USA), while HepG2 cells were cultured in 
Dulbecco’s modified essential medium DMEM (Invitrogen, USA). Both media were supplemented 
with  10%  heat  inactivated  fetal  bovine  serum  (Invitrogen,  USA),  100  units/mL  Ampicillin  and  
100 mg/mL of streptomycin. The cells were incubated at 37 ° C in humidified incubator with 5% CO2.  
3.3. Quantitative Real Time PCR 
Tissue samples were cut and 30 mg of each sample was weighed and ground. To investigate the 
effect of RAGE siRNA, Huh7 cells were cultured in 6-well plate and divided into three groups; the 
siRNA group (transfected with RAGE siRNA), the negative control group (transfected with negative 
control  RNA  to  prevent  induction  of  nonspecific  cellular  events  caused  by  introduction  of  the 
oligonucleotide into cells) and the blank control group. However, to investigate the effect of HMGB1, 
Huh7 cells were cultured in 6-well plate and divided into two groups, one group was treated with  
100 ng/mL human recombinant HMGB1 (PROSPEC, USA), while the other group was kept as a blank 
control. After 24 h, culture media were removed and the cells were washed with PBS. Total RNA from 
the tissue samples and cell cultures was isolated with Trizol (Invitrogen, USA) and converted to cDNA Int. J. Mol. Sci. 2012, 13  5993 
 
 
by  reverse  transcription.  qRT-PCR  amplifications  were  performed  with  a  PCR  Mastercycler
® 
epgradient Eppendorf (Germany). Amplification was carried out in 20 μL reactions containing 0.8 μL 
of primer, 10 μL of Platinium SYPR Green qPCR SuperMix-UDG (Invitrogen, China), and 1 μL of 
cDNA. To compare treated group to blank group, the ΔCt of each group was calculated by formula: 
ΔCt1  =  Cttreated  −  Ctβ-actin  and  ΔCt2  =  Ctblank  −  Ctβ-actin.  ΔΔCt  was  calculated  by  
(ΔCt2 − ΔCt1). The fold-change for gene expression levels of the treated groups were calculated using 
2ΔΔCt.  To  compare  neoplastic  to  para-neoplastic,  the  ΔCt  was  calculated  by  formula:  
ΔCt1  =  Ctneoplastic  −  Ctβ-actin  and  ΔCt2  =  Ctpara-neoplastic  −  Ctβ-actin.  ΔΔCt  was  calculated  by  
(ΔCt2 − ΔCt1). The fold-change for gene expression levels of neoplastic group was calculated by 
formula 2ΔΔCt. 
The primer sequences used for RAGE qRT-PCR were: 5'-GGCTGGTGTTCCCAATAAGG-3' and 
3'-TCACAGGTCAGGGTTACGGTTC-5'.  
NF-κB  P65  primer  sequences  were:  5'-TGCTGTGCGGCTCTGCTTCC-3'  and  3'-AGGCTC 
GGGTCTGCGTAGGG-5'.  
β-actin  was  used  as  a  control  for  RNA  integrity  with  the  following  primers  sequences:  
5'-GACAGGATGCAGAAGGAGATTACT-3' and 3'-TGATCCACATCTGCTGGAAGGT-5'. 
3.4. Western Blot 
Tissue samples  were cut  and  10  g  of each sample was  weighed  and  ground. Huh7  cells  were 
cultured and either transfected with RAGE siRNA or treated with HMGB1 as described in Section 3.3. 
After 48 h of incubation, culture media were removed and the cells were washed with PBS. Total 
protein from tissue samples and cell cultures was extracted by RIPA buffer (Beytime, China). After 
that, the protein amount was measured by BCA method (Beytime, China). 40 μg of the total protein 
was  loaded  and  separated  on  a  12%  Acrylamide/Bis  gel  (Beytime,  China)  and  the  protein  was 
transferred to a PVDF membrane. The PVDF membrane was blocked with 5% Bovine Serum Albumin 
(BSA) in TBST. RAGE mouse monoclonal antibody (Santa-Cruz, USA) was diluted in BSA/TBST 
solution (1:500) and used to detect RAGE protein in the tissue samples. NF-κB p65 mouse monoclonal 
antibody (Santa-Cruz, USA) was diluted in BSA/TBST solution (1:500) and used to detect NF-κB p65 
protein in cell cultures. The PVDF membrane was incubated with the antibody for 30 min at room 
temperature and over night at 4 °C  and then washed three times (10 min each) with TBST. After that, 
the PVDF membrane was incubated with HRP-labeled mouse IgG secondary antibody (Santa-Cruz, 
USA) diluted in TBST (1:1000) for 1 h and then washed three times (10 min each) with TBST. Protein 
bands were examined by ECL chemiliumenescent reagents (Beytime, China). Band intensities were 
measured and protein signals were normalized with β-actin. 
3.5. Transfection and Selection of siRNA 
Three  siRNA  (R1,  R2  and  R3)  and  one  negative  control  (NC)  RNA  were  synthesized  by 
GenePharma Company (Shanghai, China). The sequences of the RNAs were as follow: 
R1: 5'-CACUGGUGCUGAAGUGUAATT-3' 
5'-UUACACUUCAGCACCAGUGTT-3' Int. J. Mol. Sci. 2012, 13  5994 
 
 
R2: 5'-CUCCUCAAAUCCACUGGAUTT-3' 
5'-AUCCAGUGGAUUUGAGGAGTT-3' 
R3: 5'-GACCAACUCUCUCCUGUAUTT-3' 
5'-AUACAGGAGAGAGUUGGUCTT-3' 
NC: 5'-UUCUCCGAACGUGUCACGUTT-3' 
5'-ACGUGACACGUUCGGAGAATT-3' 
Huh7 Cells in logarithmic growth phase were collected and dispensed in 6-well culture plate in  
2 mL volumes. After 12 h, cells were transfected independently with R1, R2, R3 or the negative 
control  RNA  (NC)  as  follow:  100  pmol  of  the  siRNA  was  added  into  250  μL  of  Opti-MEM  
Reduced-Serum Medium (Invitrogen, USA) and mixed gently. At the same time, 5 μL of Lipofectamin 
(Invitrogen, USA) was added into 250 μL of Opti-MEM. After 5 min the Opti-MEM including siRNA 
was mixed gently with the Opti-MEM including the Lipofectamin. After 20 min the mixture was 
added into the wells and plates were incubated at 37 °C  and 5% CO2 for 24 h.  
3.6. MTT Assay 
Cell proliferation assay was performed with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT). Briefly, Huh7 cells in logarithmeic growth phase were collected and dispensed in  
96-well culture plate in 200 μL volumes. The cells were cultured and either transfected with RAGE 
siRNA or treated with HMGB1 as described in Section 3.3. The cells were then incubated at 37 °C  and  
5% CO2 for 0, 24, 48, and 72 h. The MTT solution was prepared by mixing 5 mg of MTT powder with 
10  mL  PBS,  and  sterilized  by  passing  through  0.22  μm  filter  unit.  At  the  end  of  each  indicated 
incubation interval, the cells were washed with PBS buffer and 50 μL of the MTT solution was added 
into each well. The plates were incubated for 4 h at 37 °C  and 5% CO2. Then, the MTT solution was 
removed and 150 μL of DMSO was added into each well. Finally, the absorbance (A value) was 
measured using a micro-culture plate reader at 490 nm. Cell proliferation inhibition rate by RAGE 
siRNA was calculated according to the following equation: inhibition rate = [(absorbance value of 
blank control group at 490 nm) − (absorbance value of the transfected group at 490 nm)/absorbance 
value of blank control group at 490 nm] ×  100. The increase in cells growth caused by HMGB1 was 
referred to as “the activation rate” and was calculated according to the following equation: activation 
rate = [(absorbance value of HMGB1 group at 490 nm) − (absorbance value of blank control group at 
490 nm)/absorbance value of blank control group at 490 nm] ×  100. 
3.7. Cell Cycle Analysis 
Huh7 cells were cultured into 6-well culture plates and either transfected with RAGE siRNA or 
treated with HMGB1 for 24 h as described in Section 3.3. Treated cells were harvested with trypsin, 
then washed once with 4 °C  PBS and fixed in cold 75% ethanol at 4 °C . Cells were then washed once 
again  with  4  °C   PBS  and  re-suspended  with  PBS,  then  stained  with  10  μg/mL  propidium  iodide 
(Beijing Dingguo, China) and 0.5 mg/mL RNase A solution (Fermentas, EU) for 30 min at 37 °C  in 
dark. Stained cells were immediately subjected to analysis by flow cytometry. The proportion of cells 
in each phase of the cell cycle was determined by a FACScan for Quantitative Cell Analysis.  Int. J. Mol. Sci. 2012, 13  5995 
 
 
3.8. Statistical Analysis 
ImageJ software was used to measure the size and percentage of DNA and protein bands on the gels 
and  films.  All  data  were  analyzed  using  SPSS  11.5  software  package  for  Windows  and  were 
summarized as mean ±  SE. One-way ANOVA was used to compare the data among three or more 
groups;  Student’s  t-test  was  used  to  compare  two  groups.  For  all  tests,  a  two-sided  probability  
(p < 0.05) was considered statistically significant. 
4. Conclusions  
We demonstrated that RAGE regulates the proliferation of hepatocellular carcinoma. Inflammatory 
signals initiated by RAGE contribute greatly to hepatocarcinogenesis. This indicates that RAGE gene 
could be a potential target for future gene therapy researches to find treatments for many malignancies, 
including HCC. Another means of reducing cellular proliferation could be through the use of NF-κB 
inhibitors or RAGE specific antibodies; however, this requires further investigations. 
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